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ADAM = a disintegrin and metalloproteinase; CSF-1 = colony-stimulating factor-1; ECM = extracellular matrix; EGFR = epidermal growth factor
receptor; ER = estrogen receptor; FGF = fibroblast growth factor; FGFR = FGF receptor; GH = growth hormone; IGF-1 = insulin-like growth
factor-1; IGF-1R = IGF-1 receptor; MMP = matrix metalloproteinase; PR = progesterone receptor; PTHrP = parathyroid hormone-related protein;
RANK = receptor activator of nuclear factor κB; TEB = terminal end bud; TGF = transforming growth factor; TIMP = tissue inhibitor of metallopro-
teinases.
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Abstract
Part of how the mammary gland fulfills its function of producing
and delivering adequate amounts of milk is by forming an extensive
tree-like network of branched ducts from a rudimentary epithelial
bud. This process, termed branching morphogenesis, begins in
fetal development, pauses after birth, resumes in response to
estrogens at puberty, and is refined in response to cyclic ovarian
stimulation once the margins of the mammary fat pad are met. Thus
it is driven by systemic hormonal stimuli that elicit local paracrine
interactions between the developing epithelial ducts and their
adjacent embryonic mesenchyme or postnatal stroma. This local
cellular cross-talk, in turn, orchestrates the tissue remodeling that
ultimately produces a mature ductal tree. Although the precise
mechanisms are still unclear, our understanding of branching in the
mammary gland and elsewhere is rapidly improving. Moreover,
many of these mechanisms are hijacked, bypassed, or corrupted
during the development and progression of cancer. Thus a clearer
understanding of the underlying endocrine and paracrine pathways
that regulate mammary branching may shed light on how they
contribute to cancer and how their ill effects might be overcome or
entirely avoided.
Introduction
Branching morphogenesis is fundamental to the formation of
diverse ramiform tissues from the tracheal networks of
insects to the lungs, kidneys and salivary glands of higher
organisms [1]. Although the final forms and functions of these
many arborized organs clearly differ, many of the major
mechanisms that underlie their morphogenesis seem to be
conserved in all branched organs, whereas other specialized
mechanisms are undoubtedly responsible for their individual
tissue-specific and species-specific characteristics. Thus
both ubiquitous and unique mechanisms govern the
branching process in each particular organ and organism. In
general, this process entails the initial specification and
formation of an organ anlage, its invagination, the initiation
and outgrowth of its earliest branches, its spatial organization
via reiterative branching events and tissue remodeling, the
formation of a continuous lumen, and tissue-specific
differentiation of the entire network and its terminal
structures. Indeed, many salient aspects of branching
morphogenesis are well or partly understood [1-4], whereas
many others are waiting to be solved. This article discusses
our current sense and understanding of branching morpho-
genesis in the context of mammary gland development, with
the realization that many of these notions also apply to other
areas of development and disease.
The mammary gland, unlike other branched organs,
undergoes most of its branching during adolescent rather
than fetal development. In mice, mammary development
begins shortly after mid-gestation, when bilateral epidermal
ridges (or milk lines) form from forelimb to hindlimb, along
which five pairs of disk-shaped placodes form at the site of
each future nipple (this stage of mammary development is
reviewed in the initial article in this series [5]). Each distinct
placode then invaginates to form a bulb-shaped bud (the
primary mammary rudiment or anlage) that penetrates the
underlying mesenchyme and enters the cluster of
preadipocytes that becomes the mammary fat pad. A limited
number of branches then sprout from the invading anlage so
that a rudimentary ductal tree occupying a small portion of
the overall fat pad is present at birth. This rudimentary gland
grows just enough to keep up with normal body growth until
puberty, at which point robust hormone-dependent branching
begins. At this stage, bulbous terminal end buds (TEBs) form
at the tips of the ducts and penetrate farther into the fat pad
as the ducts elongate (the biology of TEBs is reviewed more
extensively in the second article in this series [6]). New
primary ducts then form by bifurcation of the TEBs, and
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secondary side-branches sprout laterally from the trailing
ducts until the entire fat pad of the young adult is filled by an
extensive system of branched ducts (Figs 1 and 2).
Thereafter, short tertiary side-branches form along the ducts
in response to cycling ovarian hormones, further filling out the
mature ductal tree. In addition, lobulo-alveolar structures
develop like leaves at the ends of tertiary branches; however,
the mechanisms that regulate their development and
differentiation are distinct from those that govern ductal
development (and will be reviewed in the next article in this
series). Moreover, because some serial and limiting-dilution
mammary transplants form pure ductal structures, whereas
others form only alveolar outgrowths, distinct ductal and
alveolar progenitor cells are probably scattered throughout
the ductal tree.
Mammary development in humans is slightly different. Limited
data from first-trimester human embryos also reveal the
formation of a bilateral mammary ridge (or milk line) followed
by the appearance of distinct placodes, the formation and
ingrowth of mammary bulbs, and initial budding of the nascent
mammary cone [7]. In addition, there is a conspicuous
absence of hair pegs around the mammary anlagen
reminiscent of lateral inhibition. As in mice, a rudimentary
ductal tree then forms during the latter stages of embryonic
development via progressive elongation, canalization and
branching of the anlage. However, fetal exposure to maternal
hormones results in limited secretory activity and the
production of colostrum in the late-term fetus and newborn
infant that is otherwise absent in rodents. Once these
maternal influences subside, the infant breast undergoes
menopausal-like involution, after which residual ductal
structures persist in a relatively quiescent state until puberty.
To this point, human breast development in males is
indistinguishable from female breast development, whereas in
mice, androgen-dependent condensation of the mesenchyme
surrounding the neck of the mammary bud results in
destruction of the male mammary rudiment on or near
embryonic day 14. After puberty, the female human breast
undergoes variable amounts of TEB formation, duct elongation,
dichotomous and lateral branching, terminal duct lobular unit
formation and stromal expansion, whereas the male breast
remains quiescent but capable of further development under
certain circumstances (such as gynecomastia).
Mammary branching may thus be separated into embryonic,
adolescent and adult phases, each of which is differentially
regulated. For instance, adolescent branching requires
estrogen and estrogen receptor-α (ER-α), adult tertiary side-
branching requires progesterone and its receptor (PR), and
embryonic branching is hormone independent, because it
occurs in mice lacking ER-α, ER-β, PR or the receptors for
growth hormone (GH) and prolactin [8,9]. Branching is also
coordinated by local cross-talk between the developing duct
epithelium and nearby stromal cells. Indeed, tissue
transplantation studies in which mammary epithelium and
salivary mesenchyme [10] or skin epithelium and mammary
mesenchyme [11] were recombined demonstrate that
Figure 1
Nuclear-stained wholemounts illustrating ductal branching morphogenesis of the abdominal (no. 4) mammary gland. (a) Embryonic day 18.5; 
(b) age 3 weeks; (c) age 4.5 weeks; (d) age 11 weeks. Ductal penetration into the mammary fat pad can be judged with respect to the nipple and/or
main lactiferous duct (arrowhead), central lymph node (LN), distal LN (as seen in (d)) and fat pad margins. Terminal end buds are readily apparent in
the growing 4.5-week gland, and short tertiary branches are apparent in the mature 11-week gland. Scale bars, 0.5 mm (a) and 1 mm (b–d).Page 3 of 11
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mesenchymal cues control the branching pattern of the
epithelium, regardless of epithelial origin. Likewise, similar
studies show that stromal rather than epithelial or systemic
factors dictate the different mammary side-branching patterns
seen in different mouse strains [12]. A major difference
between human and murine mammary glands is the dense,
fibroblastic interlobular stroma and loose intralobular stroma
of the human breast compared with the adipose-rich stroma
seen in rodents. Nevertheless, xenotransplant studies support
the notion that stromal influences also regulate human breast
development. Indeed, the major mechanisms that regulate
mammary morphogenesis are probably similar in all mammals.
Thus this review outlines our basic understanding of the initial
endocrine stimuli and local molecular interactions that
regulate mammary branching in rodents as a model for
mammary morphogenesis in general.
Endocrine regulation of branching
morphogenesis
It has long been known that ovarian and pituitary hormones
are essential for post-pubertal mammary morphogenesis and
that estrogens can rescue mammary development in
ovariectomized [13], but not hypophysectomized, animals
[14]. However, estrogens can restore TEB and duct develop-
ment in hypophysectomized, ovariectomized rats if GH or
insulin-like growth factor-1 (IGF-1) is also provided, whereas
pituitary prolactin will not suffice [14]. This suggests that GH
is the critical pituitary hormone and that its effects are elicited
through IGF-1. Indeed, adolescent ductal development is also
impaired in mice lacking GH receptor [15], IGF-1 [14], ER-α
[8], or the aromatase responsible for estrogen biosynthesis
[16], but occurs normally in mice lacking ER-β, PR, or
prolactin receptor [8], thus confirming the importance of GH,
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Figure 2
Terminal end bud (TEB) and duct morphology. (a) High-magnification carmine alum-stained wholemount of a primary duct that has recently passed
the central lymph node (upper left corner). The bifurcating TEB is in the final stages of forming two new primary ducts with independent TEBs.
Three newly formed lateral (secondary) side-branches are also present along the trailing duct (open arrowhead), as is an area of increased
cellularity that may represent a nascent lateral bud (filled arrowhead). Increased stromal cellularity is also apparent about the bifurcating TEB. Scale
bar, 200 µm. (b) Immunophotomicrograph of a TEB illustrating its considerable proliferative activity, as indicated by the large number of cells that
have undergone DNA replication and have thus incorporated bromodeoxyuridine (brown diaminobenzidine-stained nuclei) during a 2-hour chase
period. Rather than pulling themselves forward, TEBs seem to be pushed through the adipose-rich stroma by virtue of this high proliferative activity
[6]. Hematoxylin counterstaining also reveals the stromal collar, rich in fibroblasts and collagen, that characteristically surrounds the TEB neck
(arrow) and its conspicuous absence beyond the invading distal cap. Scale bar, 100 µm. (c) Schematic diagram depicting the salient architectural
features of TEBs and their subtending ducts, including their fibroblast-rich stromal collar and high mitotic index. Though there is no evidence that
normal ductal cells ever cross the basal lamina, thinning of the basement membrane (dotted lines) does seem to occur at the tips of invading ducts
as a result of their partial enzymatic degradation and/or incomplete de novo synthesis. Stromal macrophages and eosinophils are also depicted.IGF-1, estrogen and their respective receptors. Moreover,
because IGF-1 rescues ductal development in GH-deficient
(hypophysectomized) animals, whereas excess GH and
estrogen fail to rescue IGF-1-null glands, locally produced
IGF-1 probably acts downstream of GH and/or estrogen
[14]. Indeed, the importance of local versus systemic IGF-1 is
supported by the observation that mammary branching is
significantly diminished in mutant mice with globally reduced
IGF-1 expression, but not in mice with a liver-specific deletion
of IGF-1 and a resulting 75% decrease in their circulating
rather than mammary-specific IGF-1 levels [17]. IGF-1
receptor (IGF-1R)-deficient mammary transplants also show
significantly reduced growth potential in surgically cleared
(gland-free) wild-type fat pads [18], thus revealing the
specific importance of epithelial rather than stromal IGF-1R,
whereas similar experiments show that the GH receptor is
only required in the stroma [15].
Embryonic tissue recombination studies also suggest that
only stromal ER-α is required, whereas adult tissue
transplants indicate that both epithelial and stromal ERs are
required [19]. In addition, GH induces IGF-1 and ER
expression in epithelium-free fat pads, the induction of IGF-1
is enhanced by estradiol, and only GH-treated glands express
stromal ER, further indicating that GH acts via the stroma
[14]. These data therefore support the notion that pituitary
GH, which is already present before the pubertal surge in
ovarian estrogens, acts via its receptor on mammary stromal
cells to elicit the expression of IGF-1, that stromal IGF-1 then
stimulates TEB formation and epithelial branching in a
paracrine manner, and that ovarian estrogens act in concert
with GH and IGF-1 to stimulate branching (Fig. 3).
Although estrogens induce PR expression, and
progesterone can enhance IGF-1 activity to stimulate
mammary ductal morphogenesis [20], the lack of ductal
development in ER-α-null mice is probably not due to
diminished PR function, because ablation of the gene that
encodes the two PR isoforms PR-A and PR-B via alternative
initiation has no effect on adolescent ductal development
[21]. Nevertheless, the absence of both isoforms does block
tertiary side-branching and lobuloalveolar development in
adult and pregnant mice, and their selective ablation
suggests that only PR-B is necessary and sufficient to elicit
these effects. Tissue localization and recombination data
also indicate that epithelial rather than stromal PRs stimulate
lobuloalveolar development, whereas stromal PR may
regulate tertiary branching [22,23]. Notably, Wnt4 is
regulated by progesterone and is also required for tertiary
side-branching [24]. Thus Wnt4 may act downstream of PR.
Nevertheless, the consequences of its absence fade in late
pregnancy, suggesting that other parallel pathways may also
contribute. Indeed, receptor activator of NFκB (RANK)
ligand may also participate, because it too is regulated by
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Figure 3
Provisional model depicting some of the key endocrine and paracrine signals that regulate mammary branching morphogenesis. ADAM, a
disintegrin and metalloproteinase; AREG, amphiregulin; EGFR, epidermal growth factor receptor; ER, estrogen receptor; FGF, fibroblast growth
factor; FGFR, FGF receptor; GH, growth hormone; GHR, GH receptor; IGF, insulin-like growth factor; IGF1R, IGF-1 receptor; IGFBPs,
IGF-binding proteins; MMP, matrix metalloproteinase; TEB, terminal end bud; TIMP, tissue inhibitor of metalloproteinases.progesterone [25] and because pregnancy-associated
lobuloalveolar development is impaired in knock-in mice
harboring mutations in the NFκB activator IκB kinase-α and
in mice lacking RANK or its ligand [26]. Otherwise, precisely
how progesterone regulates mammary side-branching
remains to be determined. Moreover, even though it is
dispensable for normal primary and secondary branching,
progesterone may still influence these processes in a non-
essential manner, because it can enhance the
morphogenetic effects of IGF-1 in the absence of estrogens,
namely in ovariectomized IGF-1-null mice given IGF-1 plus
progesterone [20].
Local regulation of branching morphogenesis:
the role of epidermal growth factor receptor
(EGFR/ErbB1) and ErbB2
EGFR is a receptor tyrosine kinase that elicits its effects on
binding one of seven ligands and dimerizing with another
EGFR monomer or one of three related ErbB receptors.
Notably, EGFR ligands rescue ductal development in
ovariectomized [27] and ER-α-deficient mice [28], and
exogenous estrogen elicits EGFR activation in ovariecto-
mized mice [29], suggesting that EGFR promotes mammary
branching downstream of ER-α. Several EGFR ligands
promote mammary development if given exogenously;
however, amphiregulin is the only one that is upregulated at
puberty and the only one that is required, because ductal
outgrowth is impaired in amphiregulin-deficient mice but not
in mice lacking EGF, transforming growth factor-α (TGF-α),
heparin-binding EGF-like growth factor, or betacellulin
[30,31]. EGFR is also required, but only in the stroma,
whereas its key ligand amphiregulin is exclusively expressed
and required in the epithelium [27,29-31]. Thus amphiregulin,
which is expressed as a transmembrane precursor, must be
proteolytically shed from the epithelial cell surface to activate
EGFR on nearby stromal cells. Notably, the transmembrane
metalloproteinase ADAM (a disintegrin and metallo-
proteinase)17 (TNF-α-converting enzyme; TACE) can release
amphiregulin and other EGFR ligands in culture. Moreover,
ADAM17-null mice resemble EGFR-null mice in many
respects, including the failure of their mammary glands to
develop when transplanted to viable hosts [31]. Furthermore,
as one would expect, ADAM17 is only required in the same
location as its apparent substrate, local amphiregulin
administration rescues ADAM17-null transplants, and EGFR
phosphorylation occurs only when ADAM17 and amphi-
regulin are expressed on mammary epithelial cells and EGFR
is present in the stroma. Thus ADAM17 has an essential role
in the epithelial–stromal cross-talk that regulates mammary
development by liberating an essential ligand (amphiregulin)
that is expressed only on epithelial cells so it can activate its
receptor (EGFR) on stromal cells.
The persistent failure of ADAM17-deficient glands to catch
up over time despite the presence of other related enzymes
also means that ADAM17 is the only physiologic sheddase
for amphiregulin and/or that it is independently regulated.
Interestingly, the only endogenous inhibitor of ADAM17,
tissue inhibitor of metalloproteinases 3 (TIMP-3), is
specifically downregulated in TEBs (but not trailing ducts),
whereas TIMP-1 is specifically upregulated [31]. This would
tend to enhance ADAM17-dependent processing of
amphiregulin and EGFR activation in an apt location, while
limiting the activity of other TIMP-1-inhibitable enzymes. In
addition, estrogen is a potent inducer of amphiregulin, and G-
protein-coupled receptors can stimulate ADAM17-mediated
EGFR transactivation in culture. However, the specific cues
that elicit ADAM17 activity during mammary development are
not yet known.
Nor is it clear what lies downstream of EGFR. Because TIMP-
1 inhibits mammary branching in culture and in vivo [32], but
does not inhibit ADAM17, at least one other metallo-
proteinase must be involved, and because metalloproteinase
inhibitors block branching in culture in response to EGFR
agonists [32], they are probably inhibiting enzymes that act
downstream of EGFR. By contrast, the absence of ADAM17
does not preclude branching in response to EGFR agonists
[31] because it acts upstream. Notably, EGFR activation
stimulates the expression of matrix metalloproteinase
(MMP)-2 (gelatinase-A) and the MMP-2 activator MMP-14
(MT1-MMP), and the EGFR-dependent induction of MMP-14
and subsequent activation of MMP-2 have a key role in lung
branching morphogenesis [33]. Moreover, MMP-2 regulates
mammary ductal elongation in vivo; MMP-3 (stromelysin-1),
which has not been linked to EGFR signaling, regulates side-
branching; and MMP-14, which is induced in the presumably
activated stromal cells surrounding TEBs, promotes ductal
development by activating MMP-2 and collaborating with it to
degrade type I collagen [31,32].
The possibility that fibroblast growth factors (FGFs) regulate
branching downstream of EGFR (or in a parallel pathway) is
supported by the observation that FGFs 2 and 7 support the
growth and branching of cultured EGFR-null mammary
organoids [31], whereas EGFR agonists and FGFs fail to
support the growth of organoids lacking FGF receptor 2
(FGFR2) [34]. Notably, FGFR2b is expressed on mammary
epithelial cells and is required for forming embryonic
mammary placodes, as is stromal FGF10 [5]. Moreover,
conditional ablation of FGFR2 causes a severe delay in
adolescent ductal development, and an analysis of genetic
mosaicism reveals that epithelia without FGFR2 are
eliminated from the ducts that do develop [34]. However, no
mammary phenotype has been described in FGF7-deficient
mice, possibly as a result of compensatory mechanisms, and
it remains unclear whether other FGF receptors or receptor
isoforms are involved. Nevertheless, stromal FGFs and their
epithelial receptors have key roles in branching of the
Drosophila tracheal system and in mammalian lung, salivary
gland and kidney branching, suggesting that similar
mechanisms may also influence mammary branching [1].
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kinase and potential EGFR partner ErbB2 influences ductal
morphogenesis. Transplantation of genetically rescued
ErbB2-null mammary glands to cleared wild-type fat pads
[35] and selective ablation of ErbB2 in mammary epithelial
cells [36] causes TEB defects and delays ductal
penetration, indicating that epithelial ErbB2 is required.
However, because ErbB2 has no known ligand, it requires a
coreceptor; yet ErbB4 and epithelial EGFR are expendable
and ErbB3 is weakly expressed during ductal development
[29,31,37]. Thus it remains unclear how ErbB2 regulates
ductal development or whether epithelial EGFR-ErbB2
heterodimers participate in ways that were not specifically
addressed by examining recombined EGFR-null transplants,
such as whether they influence the rate of ductal
development.
Factors that regulate embryonic mammary
branching
Some pathways may affect only the formation of the
embryonic ductal tree, others may affect only its postnatal
maturation, and still others may affect both prenatal and
postnatal development. However, the postnatal role of those
pathways that are essential for initial mammary development
may be difficult to ascertain if, in their absence, the embryonic
mammary rudiment fails to form in the first place, thus
necessitating the use of conditional approaches. For
instance, mice lacking the estrogen-regulated homeobox
transcription factor MSX2 form mammary buds that fail to
undergo embryonic branching, thus concealing any role that
MSX2 might have in adolescent branching [5]. Similarly,
instructive paracrine signaling between parathyroid hormone-
related protein (PTHrP) from the embryonic mammary bud
epithelium and its receptor PTHR1 on adjacent mesenchymal
cells is required for the formation of mammary-specific
mesenchyme, which is, in turn, required in forming a
rudimentary ductal tree [5]. Thus it is also unclear whether
PTHrP participates in subsequent branching steps, although
its overexpression during adolescent development slows
ductal elongation by increasing apoptosis in TEBs, and its
overexpression during embryogenesis somehow diminishes
ductal branching later in life [38]. Embryonic mammary
glands are also arrested at the bud stage in mice lacking the
LEF1 transcription factor that lies downstream of the
canonical (namely the β-catenin-dependent) Wnt signaling
cascade, whereas buds fail to form at all in transgenic mice
that express the diffusible Wnt inhibitor Dickkopf-1 under the
control of an epidermal (keratin14) gene promoter [5].
Nevertheless, Wnts participate in the branching of other
tissues, their transgenic overexpression affects mammary
branching, and mammary-targeted expression of an inhibitory
form of a Wnt receptor that blocks both canonical and non-
canonical Wnt signaling delays adolescent ductal
development (AMC Brown, personal communication),
suggesting that at least one Wnt signaling pathway is
involved in mammary ductal development.
The broad systemic or lethal effects of ablating a particular
molecule may also obscure its local role in embryonic and
adolescent branching, although the latter can often be
addressed through transplantation. For example, a recent
study found that development of the embryonic mammary
tree is significantly impaired in both ADAM17-null and EGFR-
null mice, yet a previous examination of EGFR-null newborns
revealed no such impairment [31]. It is therefore unclear
whether the observed delay in embryonic branching reflects
the generalized runting that results from EGFR or ADAM17
ablation, strain-specific genetic effects, the lack of local
EGFR signaling, or a combination thereof.
Ductal morphology versus branching
Although it is reasonable to predict that mechanisms that
affect TEB and duct morphology should also affect
branching, this may not always be true. Netrin-1, which acts
as a diffusible attractant and repellent during neuronal
guidance, is also secreted by the body cells of mammary
TEBs, whereas its receptor neogenin is expressed on
adjacent cap cells [39]. The absence of either netrin-1 or
neogenin causes dissociation of the cap and body cell
compartments and inappropriate migration of cap cells into
the preluminal compartment. Moreover, neogenin mediates
netrin-dependent cell clustering, further indicating that
netrin–neogenin interactions stabilize the cap cell layer and
mediate its adhesion to the preluminal body cells. Neverthe-
less, the absence of netrin-1 or neogenin has no effect on
overall branching, suggesting that ductal patterning and TEB
morphology do not depend on one another in this setting
(L Hinck, personal communication).
Hedgehog signaling, which is elicited by the binding of
Indian, Sonic or Desert hedgehog to cell surface Patched
receptors, can affect several signaling pathways that are
thought to regulate mammary branching, including the FGF,
Wnt, Notch, TGF-β, and PTHrP pathways [40]. Mammary
transplants lacking Indian or Sonic hedgehog branch normally
in cleared wild-type fat pads, indicating that neither ligand
alone is essential in the epithelium; however, conditional
haploinsufficiency of Patched-1 causes defects in duct and
TEB histology that disappear after transplantation to wild-type
fat pads, suggesting that only stromal Patched-1 is required.
Nevertheless, the overall branching pattern is unaffected.
Moreover, transplants lacking the transcription factor Gli2
that lies downstream of Patched also display normal ductal
branching despite their abnormal intra-ductal morphology,
again suggesting that ductal patterning and morphology may
not be entirely interdependent.
Conversely, some regulators, such as ErbB2, do seem to
influence both ductal morphology and branching [35]. For
example, the cell surface morphogen epimorphin is required
for growth-factor-induced branching of organotypic mammary
cultures and affects luminal diameter when provided in an
apolar manner in culture or as a mammary-targeted transgene
Breast Cancer Research    Vol 8 No 1 Sternlicht
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stromal fibroblasts seems to be required for epimorphin to
affect epithelial cells, although myoepithelial epimorphin
could potentially act in a juxtacrine manner without being
shed. As a downstream consequence, epimorphin stimulates
the expression of MMPs 2 and 3, which are also required for
proper branching morphogenesis. In addition, epimorphin
stimulates expression of the transcription factor C/EBPβ,
which is also essential for mammary morphogenesis, and
increases the relative expression of the shorter of two
C/EBPβ isoforms. Indeed, experimental manipulation of the
relative expression of these isoforms in the absence of
epimorphin signaling has the same morphogenic effect in
culture as epimorphin itself, suggesting that C/EBPβ acts
downstream of epimorphin.
The role of macrophages and eosinophils
Among the stromal cells that influence mammary development,
macrophages and eosinophils have a particularly important role
in ductal elongation and branching [42]. Macrophage
recruitment to the stroma surrounding TEBs, TEB formation
and adolescent ductal outgrowth are severely impaired in
myelosuppressed (gamma-irradiated) mice and mice lacking
macrophage-colony-stimulating factor-1 (CSF-1) or its
receptor, but are rescued by bone marrow transplantation in
irradiated mice and by exogenous CSF-1 or a mammary-
targeted CSF-1 transgene in CSF-1-null mice. Thus the
essential effects of CSF-1 on macrophage behavior are local
rather than systemic. Indeed, in the developing gland, ductal
cells produce CSF-1, whereas its receptor is expressed
exclusively on macrophages. Nevertheless, it remains unclear
whether macrophages influence ductal development via their
trophic, angiogenic, phagocytic, or matrix remodeling activities.
As regards eosinophils, their recruitment to the TEB stroma
coincides with local upregulation of their chemoattractant
eotaxin, which is recognized by the CC chemokine receptor
CCR3, and such recruitment is severely diminished in
eotaxin-deficient mice (as is ductal branching, but not
elongation) [42]. In contrast, absence of the eosinophil
chemotactic factor interleukin-5 causes a deficiency in
circulating eosinophils but has no effect on the number of
mammary eosinophils or on mammary development itself,
further supporting the importance of eotaxin as a local
chemoattractant for eosinophils during mammary
development. Although the means by which eosinophils
promote ductal branching is not entirely clear, mammary
eosinophils secrete the chemokine C10, which seems to
promote macrophage recruitment further. Thus eosinophils
and macrophages may collaborate to bring about proper
ductal morphogenesis.
Negative regulators of branching
morphogenesis
Although controls against precocious, accelerated, or excess
branching undoubtedly exist, a full understanding of their
individual importance is difficult to obtain in the face of
redundant or unrelated mechanisms. For example, the
endogenous MMP inhibitor TIMP-1 defies ductal develop-
ment in a gain-of-function setting, yet its absence has little or
no effect on branching in a loss-of-function setting [32]. Thus
it is unclear whether TIMP-1 is truly involved or compensated
for by other TIMPs, because other restraints as prevalent as
limits on the rate of cell proliferation undoubtedly continue to
exert their own rate-limiting effects. Nevertheless, each of the
branching agonists outlined in this review has its own
negative regulators (Table 1), some of which might accelerate
branching morphogenesis if lost. Indeed, some examples of
accelerated ductal development after gene inactivation have
also been seen. For instance, increased ductal invasion
occurs when the receptor tyrosine kinase signaling
antagonist Sprouty2 is inactivated in mammary epithelium,
suggesting its possible importance in controlling FGFR2
signaling [34].
Considerable evidence also indicates that TGF-β1 acts as a
key negative regulator of mammary branching by limiting
epithelial proliferation and stimulating extracellular matrix
(ECM) production [43,44]. Notably, TGF-β1 is regulated by
ovarian hormones. Moreover, mammary-targeted expression
of activated TGF-β1 causes the formation of a hypomorphic
ductal tree; slow-release TGF-β1 implants inhibit epithelial
proliferation, TEB formation and local ductal elongation; and
most notably, heterozygous TGF-β1-deficient mice, which
have less than 10% of normal TGF-β1 levels, exhibit two to
four times more proliferation than normal (15-fold more in
response to exogenous ovarian hormones) and significantly
accelerated but morphologically normal ductal development.
In addition, TGF-β1 heterozygous glands exhibit accelerated
outgrowth in wild-type fat pads, indicating that the growth
inhibitory effects of TGF-β1 are epithelial in origin. Never-
theless, these effects seem to be performed through both
autocrine feedback mechanisms and paracrine interactions
that may involve stromal type II TGF-β receptors and reciprocal
stromal responses. Thus TGF-β1 may aid in the maintenance of
proper ductal spacing by enabling neighboring ducts to avoid
one another. Moreover, TGF-β downregulates  MMP-3
expression, which would tend to defy secondary side-
branching without affecting ductal elongation, whereas it
upregulates  MMP-2 expression, which would foster ductal
elongation and thus increase the distance between
secondary branch-points [32,45].
ECM-mediated regulation of branching
morphogenesis
Substantial evidence also indicates that ECM, ECM
receptors and ECM-degrading enzymes are important
regulators of branching morphogenesis [46]. Numerous
culture-based studies show that, in addition to providing a
structural foundation for cells, ECM components convey
contextual information through cellular adhesion molecules,
such as integrins, that transmit external ECM-derived signals
Available online http://breast-cancer-research.com/content/8/1/201
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environment has been shown to affect virtually all aspects of
cell behavior, including cell shape, proliferation, survival,
migration, differentiation, polarity, organization, and
branching. Notably, α2 integrin-deficient mice, which are
unable to form integrin α2β1 collagen/laminin receptors, show
significantly diminished ductal branching, but have otherwise
normal ducts and are fully able to nurse their pups [47].
Furthermore, function-perturbing antibodies against the β1
integrin subunit cause TEB regression and diminished ductal
elongation, as do antibodies against the γ1 chain found in
most laminins, which in turn are the main basement
membrane ligands for β1 integrins [48]. These, however, are
relatively mild effects compared with the more severe
branching defects that occur when α2β1 integrin function is
blocked or absent in culture. Similarly, α3, α6, and β4 integrins
can affect branching in culture, but are not required in vivo
[49]. Thus the combined effects of multiple ECM receptors in
vivo may mitigate the effects of disrupting a single interaction.
Indeed, evidence suggests that other, non-integrin receptors
may also be involved. For example, mice lacking the discoidin
domain receptor tyrosine kinase DDR1 that signals in
response to binding triple-helical fibrillar collagens exhibit
delayed, abnormal ductal development [50]. Indeed, the
importance of fibrillar collagens as signaling molecules rather
than as mere scaffolds or barriers may help to explain the
diminished ductal development seen in mice that lack
collagenolytic MMPs 2 or 14 or that express cleavage-
resistant as well as hyper-cleavable type I collagen
(M Egeblad, MDS, BS Wiseman and Z Werb, unpublished
results). Likewise, the transgenic overexpression of β-1,4-
galactosyltransferase, a receptor for laminin and other
glycosylated proteins, causes abnormal and diminished
ductal development [51], and the laminin receptor dystro-
glycan may also participate, because it affects mammary
epithelial cells in culture and affects branching morpho-
genesis in other tissues [52].
In addition to their direct effects, various ECM components
bind and sequester other signaling molecules that affect
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Table 1
Regulators of mammary morphogenesis and their agonists, antagonists, downstream targets and realm of influence
Regulator Agonists Antagonists Targets Effects
GH-R (st) GH (pit) IGF-1 (st) General
IGF-1R (ep) IGF-1 (st) IGFBPs (st) Unknown General
ER-α (st/ep) E1/E2 (ov) Amphiregulin et al. General
PR-B (st?) ER, P (ov) Wnt4, RANKL Tertiary branching
EGFR (st) Amphiregulin (ep) Sprouty? MMPs, FGFs et al. General
Amphiregulin (ep) ER, ADAM17 (ep) HSPGs EGFR (st) General
ADAM17 (ep) PPCs et al. TIMP3 (ep) Amphiregulin (ep) General
MMP-14 (st) EGFR, PPCs et al. TIMPs 2–4 MMP-2, Coll I General
MMP-2 (st?) TGF-β, ER, MMP-14 TIMPs 1–4 Coll I et al.? Elongation
MMP-3 (st) Epimorphin et al. TGF-β, TIMPs Unknown Secondary branching
FGFR2 (ep) FGFs (st) Sprouty2 (ep) Unknown TEBs
ErbB2 (ep) Unknown Unknown Unknown TEBs
Epimorphin (st/me) Metalloenzymes Unknown C/EPBβ, MMPs Branching
TGF-β1 (ep) ER, MMPs, plasmin LAP TGF-βRI/II, MMPs Spacing
CSF-1R (mφ) CSF-1 (ep) Mφ recruitment TEBs
CCR3 (eos) Eotaxin Eos recruitment Branching
Integrin α2β1 (ep) Laminins, collagens TEBs, ducts
DDR1 (ep) Collagens TEBs, ducts
ADAM, a disintegrin and metalloproteinase; CCR, CC chemokine receptor; Coll, collagen; CSF, colony-stimulating factor; DDR, discoidin domain
receptor; EGFR, epidermal growth factor receptor; eos, eosinophil; ep, epithelial; E1/E2, estrone/estradiol; ER, estrogen receptor; FGF, fibroblast
growth factor; FGFR, FGF receptor; GH, growth hormone; GH-R, growth hormone receptor; HSPG, heparan sulfate proteoglycan; IGF-1, insulin-
like growth factor-1; IGF-1R, IGF-1 receptor; IGFBPs, IGF-binding proteins; LAP, latency-associated peptide; me, myoepithelial; MMP, matrix
metalloproteinase; mφ, macrophage; ov, ovarian; pit, pituitary; PPC, proprotein convertase; P, progesterone; PR, progesterone receptor; RANKL,
receptor activator of nuclear factor κB (RANK) ligand; st, stromal; TEB, terminal end bud; TGF, transforming growth factor; TIMP, tissue inhibitor of
metalloproteinases. Required sources are provided in parentheses.branching, such as amphiregulin, FGFs, Wnts, TGF-β, and
IGF-binding proteins 1 to 6. Thus enzyme-mediated ECM
remodeling can remove physical barriers and existing ECM
signals, reveal hidden structural information, and release
otherwise sequestered signaling molecules. Indeed, ECM-
degrading MMPs seem to have a path-clearing role in
branching morphogenesis as well as an indirect cell signaling
role that may reflect their ability to alter extant ECM signals,
generate bioactive ECM fragments (for example cryptic
integrin-binding sites on fibrillar collagen and a laminin-5
fragment that elicits epithelial cell motility), cleave cell–cell
adhesion proteins (for example E-cadherin), remove cell
surface receptors (for example FGFR1), release ECM-bound
growth factors, inactivate IGF-binding proteins, activate latent
TGF-β1, and recruit other cell types to the surrounding
stroma [32,45]. In addition, the spatial deposition of new
matrix barriers is likely to influence ductal branch-point
selection. For example, localized fibronectin deposition is
essential for salivary gland cleft formation and is associated
with a switch from E-cadherin-mediated cell–cell adhesion to
α5β1 integrin-mediated cell–matrix adhesion [53]. Thus
similar mechanisms may also influence mammary branching.
Another fundamental aspect of ductal morphogenesis that
depends, in part, on the three-dimensional matrix micro-
environment is lumen formation; that is, the assembly of
hollow polarized cysts (alveoli) and tubes (ducts). This
process seems to be driven by an intrinsic program whereby
adherent epithelia seek to establish basal, lateral, and free
apical surfaces via cell–cell, cell–matrix and associated
cytoskeletal interactions [4]. In addition, canalization may
involve anti-adhesive mechanisms that promote the
separation of apposed membranes and the apoptotic or
autophagic removal of cells from the luminal space. In
conjunction with these hard-wired mechanisms for forming
polarized luminal structures, organotypic culture data suggest
that new mammary ducts and alveoli develop by a continuous
‘rubber-sheet deformation’ mechanism in which free, lateral,
and basal cell surfaces are maintained as the adherent
epithelia bulge outward to form new hollow evaginations [4].
In addition, the tunneling process that follows invading TEBs
seems to involve the clearance of centrally located body cells
by apoptosis. Thus mammary tubulogenesis seems to involve
both budding and cavitation rather than any of the other
mechanisms by which tubular tissues can develop (as
reviewed elsewhere [3,4]).
Notably, mammary ducts are bilayered tubes composed of
inner luminal epithelial cells surrounded by myoepithelial cells,
which are in turn surrounded by an extracellular basement
membrane. In addition to fostering oxytocin-induced milk
ejection by virtue of their contractile activity, myoepithelial
cells are the cells that actually contact the basement
membrane directly and are required for the production of
many of its components, including laminins. Thus they are
ideally situated to transmit structural morphogenetic
information from the basement membrane to the luminal
epithelia. Indeed, isolated luminal epithelial cells (which do
not form their own basement membranes) fail to form properly
polarized hollow spheres when cultured in type I collagen
gels and instead form solid lumen-less structures with reverse
polarity unless myoepithelial cells are also added, in which
case they do form aptly polarized, hollow, bilayered acinar-like
structures [54]. Moreover, laminin-1 or minor amounts of
reconstituted basement membrane (but not laminins 5 or
10/11) are also able to rescue the polarity of cultured luminal
cells in the absence of myoepithelial cells. Conversely,
alveolar morphogenesis (that is, the proper positioning of
luminal and myoepithelial cells) is blocked by peptides that
interfere with their desmosomal cell–cell interactions [55].
Thus myoepithelial cells and the basement membrane
components that they produce (particularly laminin-1) seem
to provide a key link in establishing proper ductal polarity and
lumen formation, as does their cell–matrix adhesion and their
desmosomal adhesion to neighboring luminal cells.
Perspectives
Several organs undergo branching morphogenesis and there
are clear differences in how branching proceeds in different
tissues and species. Nevertheless, many of the major
mechanisms that regulate branching in one tissue are likely
to be evolutionarily conserved among all branched organs
and organisms. Indeed, many mechanistic similarities have
been seen between different branched tissues in species as
dissimilar as flies and mice [1]. However, there must also be
unique mechanisms that elicit tissue-specific and species-
specific differences. The challenge, of course, is to decipher
these ubiquitous and unique mechanisms. In addition, the
various types of mammary branching that occur (primary,
secondary and tertiary) seem to use distinct mechanisms
both at the level of signaling (that is, the cues that initiate
and orchestrate their formation) and at the level of their
physical formation (for example, the bifurcation of TEBs to
form primary ducts differs from the eruption of secondary
side-branches). However, despite considerable headway,
our understanding of the complex cascade of signals that
pass back and forth between neighboring cells of
developing tissues, their systemic regulation, and the role of
the matrix microenvironment is still largely incomplete,
leaving the field ripe for further progress. Moreover, the
same general processes, from proliferation to invasion, that
take place during normal mammary development also occur
in malignant disease, and most of the developmental
pathways that influence branching have been associated, to
some degree or other, with the development or progression
of cancer. Thus a better understanding of the mechanisms
that regulate mammary branching morphogenesis should
provide critical new insight into other normal and pathologic
processes.
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